Liposinol™ sales break three million units mark, resulting in first full year retail sales of just over USD100 Million!

Sales of InQpharm’s leading anti-obesity brand, Liposinol™ (marketed as LIPObind™ in some markets), have passed the three million mark, with the three millionth pack sold in mid-November 2007. This translates to retail sales for 2007 of over USD100million, making Liposinol™ a major player in the all important weight-management industry, especially in Europe!

Launched in March 2006, Liposinol™ sales hitting the three million mark is a tremendous achievement for a completely new product that has only been available for just over eighteen months and then only in a few markets. Today, being available in nearly 30 markets and at current production rates, nearly 400,000 tablets are sold daily ! This translates to more than four consumers take a Liposinol™ tablet every second of every day, somewhere in the world.

Proud to announce this achievement, Mr Alex Lacheta, Global Business Development Director of InQpharm said: “This success in the market gives us the clarity and certainty to build on the remarkable progress we have already made. Together with our global strategic partners, we have an ambitious vision to strengthen further our market position in order to lead in the weight management sector. InQpharm expects strong sales in the first quarter of 2008 for Liposinol™ . In addition, our expansion plans are focused on introduction of the product into into many more markets and increase InQpharm’s global presence.”

Liposinol™ is made from a patented fibre complex of a natural organically certified source. It is clinically proven to bind up to 26.6% of the dietary fat in an average western meal making it effective for weight management, treatment of obesity and, according to a recent clinical trial, also in the reduction of blood cholesterol. In the EU, Liposinol™ is certified as a medical product under MDD 93/42/EEC.

Commenting on the product, Mr Lacheta notes: “Since its launch, Liposinol™ has made a strong start in establishing its presence in the weight management market. We have an excellent product with scientifically proven efficacy and safety profiles. This places Liposinol™ in a position above other products in the market, especially those with doubtful efficacy. In addition, since Liposinol™ is a natural product with ‘mechanical fat binding action’, it is the favoured alternative to ‘pharmacologically active’ products, which often also have some very undesirable side effects.”

For further information please email: enquiries@inqpharm.com